医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Mearth Donates Electric Scooters to Australian Healthcare Workers

2020年04月16日 PM03:00
このエントリーをはてなブックマークに追加


 

SYDNEY

Electric Scooter Manufacturer Mearth has donated dozens of their Mearth X and Mearth X Pro electric scooters to healthcare workers around New South Wales.

“Healthcare workers can benefit greatly from the convenience that electric scooters bring, especially now more than ever,” said Ming YE, owner of Mearth. “Mearth electric scooters help them practise better social distancing and ease up their travel worries. With some of them completing up to 12-hour shifts and only taking public transport, this is a big help.”

Mearth has already distributed several electric scooter units to nurses and essential workers in hospitals like Macquarie University Hospital, Meditech Staffing, Mater Hospital Sydney, Royal North Shore, and Royal Prince Alfred Hospital.

With the strict regulations surrounding the use of electric scooters in NSW, the company is also looking to reach out to healthcare workers located in Queensland where electric scooter regulations fare better. Mearth is currently updating their inventory to make it possible to donate to more hospitals.

While electric scooter ride-sharing companies have pulled the plug in several cities worldwide, manufacturers like Mearth see a rise in demand. The importance of personal electric scooters and electric bikes are now becoming more obvious because they’re convenient and easy to use for quick errands. They also don’t take up parking spaces, which make them workable alternatives to cars.

About Mearth

Mearth www.mearth.com.au is a Sydney based manufacturer and seller of electric scooters and electric bikes. The company’s goal is to use innovation to disrupt and reshape current forms of transportation to be more efficient and convenient.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200415005834/en/

CONTACT

Gizel Salabao

Digital Marketing Manager

sales@mearth.com.au

+61488824503

同じカテゴリーの記事 

  • La Jolla Institute for Immunology and RevolKa started a Research Collaboration
  • U.S. FDA Approves Subcutaneous Administration of Takeda’s ENTYVIO® (vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn’s Disease
  • ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
  • Renesas’ New FemtoClock™ 3 Timing Solution Delivers Industry’s Lowest Power and Leading Jitter Performance of 25fs-rms
  • 成人向け予防接種プログラムは初期投資の19倍もの社会経済的価値をもたらすとの新レポートを発表